CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study Evaluating the Safety and Efficacy of the Combination of Zanubrutinib Plus Lisocabtagene Maraleucel for Richter's Syndrome

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05873712
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:19.160651+00:00
Published At: 2026-03-03T00:00:00+00:00
Record Updated At: 2026-03-03
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Recurrent Transformed Chronic Lymphocytic Leukemia", "Refractory Transformed Chronic Lymphocytic Leukemia", "Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma", "Recurrent Transformed B-Cell Non-Hodgkin Lymphoma", "Recurrent Transformed Non-Hodgkin Lymphoma", "Refractory Transformed Non-Hodgkin Lymphoma", "Refractory Transformed B-cell Non-Hodgkin Lymphoma", "Refractory Transformed"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-03-03"
protocolSection.identificationModule.nctId: "NCT05873712"
protocolSection.identificationModule.officialTitle: "A Phase II Study Evaluating the Safety and Efficacy of the Combination of Zanubrutinib Plus Lisocabtagene Maraleucel for Richter\u0027s Syndrome"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.